← Leaderboards
Jean-Pierre H Perchellet
Kansas State University
$982,125
Attributed
$982,125
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$982,125 · 1
By mechanism
R01$982,125 · 1
Top collaborators
No co-investigators on record.
Most similar at Kansas State University
Same institution · by research overlap
- Michael R. Kanost$10,753,552
- Haobo Jiang$5,154,083
- Zhilong Yang$4,616,938
- Nicholas A Wallace$2,218,099
- Michael R Kanost$944,544
Others in their field
Top investigators on “Antineoplastics”
- David Heimbrook · Leidos Biomedical Research, Inc.$245,744,647
- Leonard Freedman · Leidos Biomedical Research, Inc.$243,278,693
- Charles A Coltman · Southwest Oncology Group$134,454,243
- Gregory H Reaman · National Childhood Cancer Foundation$112,139,479
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,166,869
- Richard L Schilsky · University Of Chicago$90,728,118
Research focus
AntineoplasticsApoptosisCell CycleChemical Structure FunctionCombination ChemotherapyCysteine EndopeptidasesDna DamageDna ReplicationDna TopoisomerasesDrug Design /Synthesis /ProductionDrug MetabolismDrug Screening /EvaluationEnzyme ActivityLaboratory MouseLung NeoplasmsMelanomaMembrane Transport ProteinsMultidrug ResistanceNeoplasm /Cancer ChemotherapyNonhuman Therapy EvaluationNucleic Acid ProbesPurinesPyrimidinesQuinones
Grant awards (5)
TRIPTYCENE ANALOGS--NOVEL BIFUNCTIONAL ANTICANCER DRUGS$196,425
R01 · FY2004 · CA
TRIPTYCENE ANALOGS--NOVEL BIFUNCTIONAL ANTICANCER DRUGS$196,425
R01 · FY2003 · CA
TRIPTYCENE ANALOGS--NOVEL BIFUNCTIONAL ANTICANCER DRUGS$196,425
R01 · FY2002 · CA
TRIPTYCENE ANALOGS--NOVEL BIFUNCTIONAL ANTICANCER DRUGS$196,425
R01 · FY2001 · CA
TRIPTYCENE ANALOGS--NOVEL BIFUNCTIONAL ANTICANCER DRUGS$196,425
R01 · FY2000 · CA